What type of study is this?

This is a Animal Study study (also classified as: Cohort Study).

December 8, 2025Blood

Hematopoietic JAK2V617F mutation increases susceptibility to atrial fibrillation via NLRP3 inflammasome activation in macrophages

View Full Paper

Ask AI

Bookmark

Authors

GTGuangshuai Teng KSKe Shang CDChenxiao Du

Discussion

Member takes

Overview

Retrospective analysis reveals JAK2V617F mutation links to increased atrial fibrillation risk in myeloid malignancies, suggesting inflammatory pathways as a target for ruxolitinib treatment.

Key Points

JAK2V617F mutation increases atrial fibrillation risk, revealing a direct causal relationship with macrophage activation.
Co-culture studies demonstrated JAK2VFBMDMs promoted fibrosis-related protein expression in atrial fibroblasts, indicated by key cytokines.
Retrospective analysis showed JAK2V617F mutation as an independent risk factor for new-onset atrial fibrillation with HR of 2.20 (95% CI: 1.45-3.35).
Ruxolitinib treatment significantly lowered incidence of new-onset atrial fibrillation in JAK2V617F-mutant patients, emphasizing inflammation's role.

Cite This Study

Teng et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d443 https://doi.org/10.1182/blood-2025-634

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

Hematopoietic JAK2V617F mutation increases susceptibility to atrial fibrillation via NLRP3 inflammasome activation in macrophages

View Full Paper

Ask AI

Bookmark

Authors

GTGuangshuai Teng KSKe Shang CDChenxiao Du

Discussion

Member takes

Overview

Retrospective analysis reveals JAK2V617F mutation links to increased atrial fibrillation risk in myeloid malignancies, suggesting inflammatory pathways as a target for ruxolitinib treatment.

Key Points

JAK2V617F mutation increases atrial fibrillation risk, revealing a direct causal relationship with macrophage activation.
Co-culture studies demonstrated JAK2VFBMDMs promoted fibrosis-related protein expression in atrial fibroblasts, indicated by key cytokines.
Retrospective analysis showed JAK2V617F mutation as an independent risk factor for new-onset atrial fibrillation with HR of 2.20 (95% CI: 1.45-3.35).
Ruxolitinib treatment significantly lowered incidence of new-onset atrial fibrillation in JAK2V617F-mutant patients, emphasizing inflammation's role.

Cite This Study

Teng et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d443 https://doi.org/10.1182/blood-2025-634

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark